OraSure Technologies Inc. of Bethlehem – a global manufacturer and distributor of oral fluid diagnostic and collection devices to detect or diagnose medical conditions – today has a new senior vice president of research and development/chief science officer.
Michael Reed brings to OraSure Technologies more than 20 years of experience in life sciences and diagnostics research and development, including globally regulated in vitro diagnostics development and commercialization of molecular and cellular applications and systems.
Reed replaces Stephen Lee, who retired in 2014 after serving as executive vice president of research and development and chief science officer for eight years. Reed spent the last eight years as part of the management team at Beckman Coulter, headquartered in Brea, Calif., a global diagnostics and life sciences company.
At Beckman Coulter, Reed held a variety of leadership positions, including director of global assay and applications development and director of scientific affairs. Under his leadership, the company launched and commercialized more than 300 products globally across multiple disciplines.
“Mike will be a valuable addition to our senior management team, and we will benefit from his global leadership in research and development and specifically his expertise in regulated assay development, genomics and molecular diagnostics,” said Douglas Michels, president and CEO of OraSure.
Prior to his tenure at Beckman Coulter, Reed was director of product development with Osmetech Molecular Diagnostics in Pasadena, Calif., where he led the effort to develop two in vitro diagnostics systems for cystic fibrosis genotyping and a pharmacogenetics test to guide blood thinner medication dosing.
A graduate of the University of Adelaide and The Australian National University, Reed conducted post-doctoral research at the Beckman Research Institute at the City of Hope in Duarte, Calif.
OraSure Technologies and its subsidiary, DNA Genotek in Ottawa, Canada, employ 320 people. The company’s portfolio of products is sold globally, including to clinical laboratories, hospitals and clinics.
Last June, OraSure announced it was awarded a three-year contract for up to $10.4 million in funding from the U.S. to advance clinical development of a rapid antigen test for Ebola – the rare and deadly African-originated disease which in 2014 made its way to the United States.